Skip to content

Revenue Climbs 22% in June Quarter as Jaidis Records ₹8,017 billion Turnover

By News Analysis India · · 1 min read

Jaidis Lifesciences, formerly known as Cadila Healthcare, posted a 22% rise in revenue for the June quarter, reaching ₹8,017 crore against ₹6,574 crore a year ago. The growth reflects expanding sales of generic drugs, vaccines, biosimilars and specialty formulations to more than 50 countries.

The firm, established in 1952 and headquartered in Ahmedabad, operates over 30 manufacturing units worldwide. Its diversified portfolio now includes consumer health brands such as Glucon‑D, Sugar Free, Complan, Niceil and Everyuth through its subsidiary Jaidis Wellness.

While top‑line numbers were encouraging, profitability metrics weakened. Net profit fell 36% to ₹940 crore and EBITDA dropped to ₹1,930 crore, pulling the EBITDA margin down to 24.1% from 31.8% a year earlier.

Market reaction was modestly positive. Shares closed at ₹1,126, marginally higher than the previous session. Over the past five days the stock registered a 1.41% rise, yet it slipped 0.52% in the last month. The six‑month performance remains strong with a 25.43% uplift, and the year‑to‑date gain stands at 23.20%.